Company profile: Axial Therapeutics
1.1 - Company Overview
Company description
- Provider of gut-restricted and gut-selective small molecule therapeutics targeting the microbiome–gut–brain axis for neurological diseases. Offerings include AB-2004, a Phase 2 therapy for irritability associated with autism that adsorbs gut bacterial metabolites, and AX-5006 for Parkinson’s. Also offers a Microbial-Inspired Therapeutics discovery platform and early-stage programs in liver disease and oncology.
Products and services
- Microbial-Inspired Therapeutics Platform: A microbiome-targeted discovery platform that identifies and develops small‑molecule therapeutics targeting the microbiome–gut–brain axis for neurological diseases and disorders
- AB-2004: A gut-restricted molecular therapy in Phase 2 clinical trials that adsorbs metabolites produced by gut bacteria to treat irritability associated with autism
- AX-5006: A gut-selective small‑molecule therapy intended to reduce bacterial amyloid aggregation in the gut for Parkinson’s disease, expected to enter clinical testing in 2024
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Axial Therapeutics
Kallyope
HQ: United States
Website
- Description: Provider of medicines developed using the science of gut-brain biology to transform human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kallyope company profile →
Adaptive Phage Therapeutics
HQ: United States
Website
- Description: Provider of phage-based therapeutic services for multi-drug resistant pathogenic bacteria, using clinical technology to match phages to patient-specific infections; offerings include BX004 for cystic fibrosis Pseudomonas aeruginosa, BX211 for diabetic foot osteomyelitis, personalized and optimized phage therapies, and the XMarker platform for microbial biomarker discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptive Phage Therapeutics company profile →
TargEDys
HQ: France
Website
- Description: Provider of functional and medical foods and medical products that harness the microbiota and hormone-mimetic proteins to regulate appetite and treat eating disorders such as hyperphagia and anorexia. Portfolio includes Hafnia alvei HA4597 and LpWJL precision probiotics, PreciBiomic oxytocin-mimetic strains for stress/anxiety, and Symbiosys Satylia distributed by Biocodex in select European countries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TargEDys company profile →
Vedanta Biosciences
HQ: United States
Website
- Description: Provider of microbiome-derived therapies that modulate the gut microbiota to address immune and infectious diseases via orally administered defined bacterial consortia. Pipeline includes VE303 for preventing Clostridioides difficile infection recurrence (Phase 2 met primary efficacy endpoint), VE202 for IBD, and VE707 for MDROs (including CRE, ESBL, VRE); backed by CARB-X research grants.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vedanta Biosciences company profile →
Infinant Health
HQ: United States
Website
- Description: Provider of infant gut microbiome solutions, offering Evivo Powder, a daily supplement for infants fed any amount of breast milk to establish a protective gut microbiome and support healthy immune function, and B. infantis EVC001, a bacterial strain discovered by Infinant Health and proven pivotal to infant immune health, particularly when combined with breast milk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Infinant Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Axial Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Axial Therapeutics
2.2 - Growth funds investing in similar companies to Axial Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Axial Therapeutics
4.2 - Public trading comparable groups for Axial Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →